Zacks: Analysts Anticipate Xenon Pharmaceuticals Inc (XENE) Will Announce Earnings of -$0.36 Per Share
Wall Street brokerages expect Xenon Pharmaceuticals Inc (NASDAQ:XENE) to announce ($0.36) earnings per share for the current quarter, Zacks reports. Zero analysts have made estimates for Xenon Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at ($0.37) and the highest estimate coming in at ($0.35). Xenon Pharmaceuticals reported earnings of ($0.21) per share during the same quarter last year, which indicates a negative year-over-year growth rate of 71.4%. The business is expected to announce its next quarterly earnings report on Tuesday, May 14th.
On average, analysts expect that Xenon Pharmaceuticals will report full-year earnings of ($1.62) per share for the current year, with EPS estimates ranging from ($1.74) to ($1.50). For the next financial year, analysts forecast that the firm will report earnings of ($1.62) per share, with EPS estimates ranging from ($1.68) to ($1.55). Zacks’ EPS averages are an average based on a survey of sell-side research analysts that follow Xenon Pharmaceuticals.
Xenon Pharmaceuticals (NASDAQ:XENE) last announced its quarterly earnings results on Wednesday, March 6th. The biopharmaceutical company reported ($0.29) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.37) by $0.08.
Xenon Pharmaceuticals stock remained flat at $$8.66 on Monday. 38,011 shares of the company’s stock traded hands, compared to its average volume of 99,533. The company has a market cap of $218.58 million, a price-to-earnings ratio of -6.51 and a beta of 1.75. The company has a debt-to-equity ratio of 0.16, a current ratio of 29.48 and a quick ratio of 29.48. Xenon Pharmaceuticals has a 12-month low of $4.50 and a 12-month high of $15.92.
Several large investors have recently modified their holdings of the company. Northern Trust Corp boosted its stake in shares of Xenon Pharmaceuticals by 18.9% in the 4th quarter. Northern Trust Corp now owns 12,246 shares of the biopharmaceutical company’s stock valued at $77,000 after purchasing an additional 1,948 shares in the last quarter. JPMorgan Chase & Co. acquired a new position in Xenon Pharmaceuticals during the 3rd quarter worth about $111,000. Scotia Capital Inc. lifted its position in Xenon Pharmaceuticals by 16.8% during the 4th quarter. Scotia Capital Inc. now owns 66,704 shares of the biopharmaceutical company’s stock worth $421,000 after buying an additional 9,618 shares in the last quarter. Virtu Financial LLC acquired a new position in Xenon Pharmaceuticals during the 4th quarter worth about $80,000. Finally, Geode Capital Management LLC acquired a new position in Xenon Pharmaceuticals during the 4th quarter worth about $88,000. Institutional investors own 69.15% of the company’s stock.
Xenon Pharmaceuticals Company Profile
Xenon Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline include XEN496, A Kv7 potassium channel modulator that is phase II clinical trials for the treatment of KCNQ2 epilepsy; XEN1101, A Kv7 potassium channel modulator, which is in phase II clinical trail for the treatment of epilepsy.
Read More: SEC Filing
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Xenon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xenon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.